Skip to main content
Fig. 2 | Journal of Biomedical Science

Fig. 2

From: Reprogramming of arachidonate metabolism confers temozolomide resistance to glioblastoma through enhancing mitochondrial activity in fatty acid oxidation

Fig. 2

The Sp1-regulated COX2/PTGS pathway in recurrent glioblastoma. Effects of multiple inhibitors, including a Pyrrophenone (left) and celecoxib (right), b Zileuton (left) and ML-355 (right) on the viability of U87MG-R cells. The cells were treated with TMZ in the presence of the indicated inhibitors for 72 h, and cell viability was determined via MTT assay. c Paired primary and recurrent glioblastoma specimens. Samples were collected from 14 patients and subjected to RNA-Seq. The red arrow-marked genes play important roles in the metabolic pathway involving the synthesis of prostaglandins from AA (the COX pathway) as shown on the right panel. d Defined promoter regions of PLA2G5, ABHD8, and PTGS2. The binding regions of Sp1 were determined via ChIP-Seq. e Sp1-induced activities of pGL2-conjugated promoter constructs, including PLA2G5, ABHD8, and PTGS2. Luciferase reporter assay was employed to analyse the promoter activities in wild type and TMZ-resistant glioblastoma cells. Data were analysed by performing two-tailed unpaired Student’s t test

Back to article page